Choreatic symptoms during and after treatment with paliperidone and escitalopram

Pharmacopsychiatry

Volumn 41, Issue 5, 2008, Pages 203-204

  Huther R ^a   Gebhart, C ^a   Mirisch, S ^a   Bauml J ^a   Förstl, Hans ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ESCITALOPRAM; LORAZEPAM; PALIPERIDONE; QUETIAPINE; VALPROIC ACID;

ADULT; AGITATION; AKATHISIA; ARTICLE; CASE REPORT; CHOREA; CHOREOATHETOSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG WITHDRAWAL; FEMALE; HUMAN; INVOLUNTARY MOVEMENT; MAJOR DEPRESSION; MYOCLONUS; NERVOUSNESS; PHARMACODYNAMICS; PRIORITY JOURNAL; PSYCHOSIS; RESTLESSNESS; RIGIDITY; SIDE EFFECT;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; CHOREA; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; ISOXAZOLES; MIDDLE AGED; PSYCHOTIC DISORDERS; PYRIMIDINES;

EID: 54749158855     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1078747     Document Type: Article

References (6)

1. Davidson M, Emsley R, Kramer M, Ford L, Pan G, Lim P, Eerdekens M. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophrenia Res 2007; 93: 117-130
2. Dremencov E, El Mansari M, Blier P. Distinct electrophysiological effects of paliperidone and risperidone on the firing activity of rat serotonin and norepinephrine neurons. Psychopharmacology 2007; 194: 63-72
3. Förstl H, Pohlmann-Eden B. Amplitudes of somatosensory evoked potentials reflect cortical hyperexcitability in antidepressant-induced myoclonus. Neurology 1990; 40: 924-926
4. Karlsson P, Hargarter L, Dencker E et al. Pharmacokinetics and dopamine D2 and serotonin 5-HT2a receptor occupancy of paliperidone in healthy subjects: two open-label, single-dose studies. Pharmacopsychiatry 2007; 40: 227
5. Meltzer H, Hargarter L, Kramer M et al. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week placebo-controlled studies. Pharmacopsychiatry 2007; 40: 222
6. Saito M, Yasui-Furukori N, Nakagami T, Furukori H, Kaneko S. Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients. J Clin Psychopharmacol 2005; 25: 527-532